Asterias Biotherapeutics (AST) Given a $11.00 Price Target at HC Wainwright

HC Wainwright set a $11.00 target price on Asterias Biotherapeutics (NYSEAMERICAN:AST) in a research report sent to investors on Monday morning. The firm currently has a buy rating on the biotechnology company’s stock.

Separately, Zacks Investment Research upgraded Asterias Biotherapeutics from a hold rating to a buy rating and set a $3.75 target price for the company in a research note on Tuesday, October 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The company has an average rating of Hold and an average target price of $8.94.

Shares of Asterias Biotherapeutics (NYSEAMERICAN AST) opened at $2.30 on Monday. Asterias Biotherapeutics has a 12 month low of $1.95 and a 12 month high of $5.00. The firm has a market capitalization of $135.38, a price-to-earnings ratio of -3.54 and a beta of 1.30.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.themarketsdaily.com/2018/01/11/asterias-biotherapeutics-ast-given-a-11-00-price-target-at-hc-wainwright.html.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply